The PI3K inhibitors market is projected to witness remarkable growth by 2034, driven by advancements in cancer treatment and the increasing prevalence of oncological disorders. Enhanced research and development activities, along with strategic collaborations, are expected to further propel market expansion. LAS VEGAS , Aug.
21, 2024 /PRNewswire/ -- DelveInsight's PI3K Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PI3K inhibitors, market share of individual therapies, and current and forecasted PI3K inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the PI3K Inhibitors Market Report As per DelveInsight's analysis, the current market size of PI3K Inhibitors is anticipated to grow significantly in the 7MM by 2034. While the first approved PI3K inhibitors were limited to hematological cancer, the therapeutic window has now broadened towards solid tumors as well.
Approximately 40% of people with HR-positive breast cancer have a PIK3CA mutation and often face poorer prognosis and resistance to endocrine treatment. The first success is Novartis' PI3K inhibitor PIQRAY (alpelisib) , which was approved in 2019 for breast cancer in combination with FASLODEX. Now, Roche's Inavolisib is the strongest player in the pipeline expected to address the first line HR-positive, HER2-negative PI3K .